NEW YORK (GenomeWeb) – Biotech start-up NanoSomix said this week that it plans to launch its exosome-based Alzheimer's assay this fall, targeting the product at academic and pharmaceutical researchers investigating the disease.

The assay isolates neuronal exosomes in patient blood and then measures their levels of the Alzheimer's biomarkers amyloid-β42 and phosphorylated tau protein. According to President and CEO John Osth, this approach lets the company measure patient biomarkers without needing to perform lumbar punctures to collect cerebrospinal fluid.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.